Abstract
New evidence indicates the importance of CD137 for controlling Epstein-Barr virus (EBV) infections. (1) Mutations in CD137 predispose to EBV-associated diseases. (2) EBV induces ectopic CD137 expression, thereby activating a negative feed-back regulation and reducing T cell costimulation. These findings suggest CD137 agonists as new treatments for EBV-associated diseases.
Author supplied keywords
Cite
CITATION STYLE
APA
Luu, K., Nickles, E., & Schwarz, H. (2020). Destroy, what destroys you. OncoImmunology, 9(1). https://doi.org/10.1080/2162402X.2019.1685301
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free